Glaukos Corp (N:GKOS)

Business Focus: Medical Devices & Implants

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
 
See Regulatory Filings on SEC
Company Contact
Address: 229 Avenida Fabricante
SAN CLEMENTE CA 92672-7531
Tel: N/A
Website: www.glaukos.com
IR: See website
<
Key People
William J. Link
Independent Chairman of the Board
Thomas William Burns
President, Chief Executive Officer and Director
Joseph E. Gilliam
Chief Financial Officer, Senior Vice President - Corporate Development
Chris M. Calcaterra
Chief Operating Officer
L. Jay Katz
Chief Medical Officer
 
Business Overview
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.
Financial Overview
For the six months ended 30 June 2019, Glaukos Corp revenues increased 35% to $112.6M. Net loss decreased 6% to $7.7M. Revenues reflect United States segment increase of 32% to $92.3M, International segment increase of 52% to $20.3M. Lower net loss reflects Interest and other expense, net increase from $1.7M (expense) to $148K (income), Interest Income increase from $505K to $1.6M (income).
Employees: 437 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $2,269M as of Jun 30, 2019
Annual revenue (TTM): $210.61M as of Jun 30, 2019
EBITDA (TTM): -$8.59M as of Jun 30, 2019
Net annual income (TTM): -$12.49M as of Jun 30, 2019
Free cash flow (TTM): $17.47M as of Jun 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 36,834,375 as of Aug 5, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization